Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

NetScientific’s Wanda to partner with Dignity Health

Healthcare tech investor NetScientific is to partner with a leading US hospital group to launch a software platform to improve cancer care.
NetScientific’s Wanda to partner with Dignity Health
OncoVerse is a cancer care software platform
Healthcare tech investor NetScientific (LON:NSCI) is to partner with a leading US hospital group to launch a software platform to improve cancer care.
 
Its operating subsidiary Wanda has inked a collaborative deal with Dignity Health to launch OncoVerse.
 
The digital platform allows clinicians to work together to establish the most effective treatment plan and helps to reduce admin costs.
 
Dignity Health is home to nearly 9,000 physicians and more than 400 care centers spanning 21 states.
 
NetScientific's chief executive Francois R. Martelet said: "Wanda is the group's lead subsidiary in our digital health franchise.
 
"The launch of Oncoverse with Dignity Health, and its huge US network, is a significant milestone for the company and further endorses its core technology.
 
"This deal marks the second partnership that Wanda has secured with a leading US healthcare group since the start of 2016 as it continues to develop more platforms to better manage chronic conditions."
 
In January Wanda inked a deal with Chicago-based Health Resource Solutions (HRS) to provide its chronic condition digital management system.
 
The organisation looks after more than 1,000 patients per month helping them to have a higher quality of life at home rather than in hospitals.
 
The first patients are expected to start using the platform in the first quarter of this year.
 
And this month the firm revealed one of its portfolio companies was to partner with the US National Cancer Institute for phase II clinical trials of a novel range of cancer immunotherapies.
 
PDS Biotechnology has signed a co-operative research and development agreement with the NCI to develop treatments using its Versamune platform for tumour-related proteins in prostate, breast, and HPV-related cancers.
 
NetScientific shares added  2.4% to stand at 85.5p.
View full NSCI profile View Profile

Netscientific PLC Timeline

Related Articles

Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Richard Lipscombe talked revenue generation and growth path with investors.
picture of doctors
July 11 2017
The focus has switched to new, higher value “finished device products”,
GW_Pharma.png
January 11 2017
“[We are] entering a very exciting phase, which should result in the crystallisation of substantial value,” said chief executive, Dr Satu Vainikka.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use